Ziza Vincent, Canaud Ludovic, Molinari Nicolas, Branchereau Pascal, Marty-Ané Charles, Alric Pierre
Department of Vascular and Thoracic Surgery, Arnaud de Villeneuve University Hospital, Montpellier, France.
Department of Vascular and Thoracic Surgery, Arnaud de Villeneuve University Hospital, Montpellier, France.
J Thorac Cardiovasc Surg. 2016 Jun;151(6):1595-1603.e7. doi: 10.1016/j.jtcvs.2015.12.030. Epub 2015 Dec 22.
Specific complications of thoracic endovascular aortic repair (TEVAR) exist and long-term data are lacking. The purpose of this study was to evaluate our long-term TEVAR results.
This is a single-center retrospective study of 223 patients undergoing TEVAR from 1998 to 2013. Indication was aneurysm (45%), traumatic (26%), dissection (23%), and septic (6%).
Patients' mean age was 62.7 ± 17.9 years, 84% of them had an American Society of Anesthesiologists score ≥3, and 42% had an aortic rupture. TEVAR was performed in zone 0 (n = 17), 1 (n = 17), or 2 (n = 59) in 42% of patients. Technical success rate was 96.4%. Overall 30-day mortality was 11.7% (elective aneurysm, 11.6%; emergent aneurysm, 34.3%; acute type B dissection, 14.8%; chronic dissection, 4.2%; septic, 8.3%; and traumatic, 1.7%). Major adverse events included stroke in 4.5%, spinal cord ischemia in 1.8%, and retrograde aortic dissection in 2.7%. Mean follow-up was 43.4 ± 38 months. Estimated aortic complications-free survivals at 12, 36, 60, and 120 months were (% ± standard error) 73% ± 3%, 64% ± 4%, 62% ± 4% and 57% ± 5%, respectively. Multivariate analysis showed that patients treated for a chronic aortic dissection had a significant risk of late reintervention (P = .001) CONCLUSIONS: Because of its simplicity and low morbimortality rate, TEVAR has become the first-line approach for thoracic aortic diseases. Mortality outcomes are related to aortic pathology, emergent status, and proximal landing zone. To improve long-term results, rigorous patient selection and follow-up, development of referral centers, and technologic evolution of materials have to be reached.
胸主动脉腔内修复术(TEVAR)存在特定并发症且缺乏长期数据。本研究旨在评估我们的长期TEVAR结果。
这是一项对1998年至2013年期间接受TEVAR的223例患者的单中心回顾性研究。适应证包括动脉瘤(45%)、创伤性(26%)、夹层(23%)和感染性(6%)。
患者的平均年龄为62.7±17.9岁,其中84%的患者美国麻醉医师协会评分≥3,42%的患者发生主动脉破裂。42%的患者在0区(n = 17)、1区(n = 17)或2区(n = 59)进行了TEVAR。技术成功率为96.4%。总体30天死亡率为11.7%(择期动脉瘤,11.6%;急诊动脉瘤,34.3%;急性B型夹层,14.8%;慢性夹层,4.2%;感染性,8.3%;创伤性,1.7%)。主要不良事件包括中风4.5%、脊髓缺血1.8%和逆行性主动脉夹层2.7%。平均随访时间为43.4±38个月。12、36、60和120个月时估计的无主动脉并发症生存率(%±标准误差)分别为73%±3%、64%±4%、62%±4%和57%±5%。多变量分析显示,接受慢性主动脉夹层治疗的患者有晚期再次干预的显著风险(P = 0.001)结论:由于其操作简单且病死亡率低,TEVAR已成为胸主动脉疾病的一线治疗方法。死亡率结果与主动脉病变、急诊状态和近端着陆区有关。为了改善长期结果,必须进行严格的患者选择和随访、建立转诊中心以及材料的技术改进。